Molecular subtyping in breast cancer

Title : Molecular subtyping in breast cancer

Abstract:

The standard of care for invasive cancers of the breast has been and continues to be to evaluate them for breast prognostic markers: estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 by immunohistochemistry. Over 2 decades ago, a study was the first to report on the molecular subtypes of breast cancer. Four main subtypes were reported. Since then there have been some changes in the molecular subtype classification, but overall many studies have shown that this subtyping has clinical prognostic and predictive value. More recently, molecular assays have been developed and studies have shown similar clinical prognostic and predictive value. The literature was reviewed for studies evaluating the clinical significance of all 3 of these methods of evaluation and the follow-up findings of that review will be presented in this talk (Lawton, TJ. Update On The Use of Molecular Subtyping in Breast Cancer. Adv Anat Pathol.

Biography:

Thomas J. Lawton is an AP board-certified surgical pathologist with over 28 years of post-fellowship experience specializing in breast pathology. He have served as a pathologist consultant and co-PI on numerous multi-disciplinary breast cancer-focused national research grants and have served as the Fred Hutchinson Cancer Research Center representative for the National Comprehensive Cancer Network’s Committee on Breast Cancer Risk Reduction. He have lectured at multiple meetings on breast cancer nationally and internationally on the molecular pathology of breast cancer, including at the XII Congreso Nacional de Mastologia in Monterrey Mexico and have co-directed two Short Courses on Breast Pathology at the United States and Canadian Academy of Pathology.